Menu
2020 Special Session I

Budget Amendments - HB5005 (Member Request)

View Budget Item
View Budget Item amendments

Chief Patron: Jones J.C.
R&D Support for COVID-19 Treatments

Item 135 #1h

Item 135 #1h

First Year - FY2021 Second Year - FY2022
Commerce and Trade
Virginia Innovation Partnership Authority FY2021 $10,000,000 FY2022 $0 GF

Language
Page 33, line 35, strike "$25,700,000" and insert "$35,700,000".

Page 33, after line 35, insert:

"Q. Out of the amounts includes in this appropriation, $10,000,000 in the first year from the general fund shall be used to accelerate the research and development of a peptide-based drug that treats acute lung injury caused by COVID-19. These funds shall only be awarded to a company with a business presence in Virginia and an approved application for a new peptide-based drug by the United States Food and Drug Administration."



Explanation

(This amendment provides $10 million in the first year from the general fund to support the acceleration of research and development by a Virginia company of a peptide-based drug company that treats acute lung injury caused by COVID-19. It further clarifies a company in receiving these funds must have an approved application for a new drug by the U.S. Food and Drug Administration. Upon enrolling, Item 135 will be set out and enrolled appropriately.)